Please login to the form below

Not currently logged in
Email:
Password:

inherited retinal disease

This page shows the latest inherited retinal disease news and features for those working in and with pharma, biotech and healthcare.

Novartis negotiates ex-US rights to Spark gene therapy

Novartis negotiates ex-US rights to Spark gene therapy

Luxturna is the first gene therapy to be approved in the US where it has a similar indication - biallelic RPE65-mediated inherited retinal disease (IRD) - and is being launched at a ... No otherwise healthy child should have to go blind due to this

Latest news

  • Spark sets Luxturna price, igniting US affordability debate Spark sets Luxturna price, igniting US affordability debate

    Luxturna is used to treat a sight-robbing disorder called biallelic RPE65-mediated inherited retinal disease (IRD), which affects somewhere between 1, 000 and 2, 000 people in the US with

  • Spark’s Luxturna becomes US’s first approved gene therapy Spark’s Luxturna becomes US’s first approved gene therapy

    The FDA has chalked up another first for 2017, approving Spark Therapeutics’gene therapy Luxturna for a sight-robbing disorder called biallelic RPE65-mediated inherited retinal disease (IRD). ... a policy framework - including the development of disease

  • Spark closes on first US gene therapy approval Spark closes on first US gene therapy approval

    Spark closes on first US gene therapy approval. FDA starts review of Luxturna for patients with inherited retinal disease. ... Luxturna (voretigene neparvovec) is under review for a condition known as biallelic RPE65-mediated inherited retinal disease

More from news
Approximately 3 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Streaming Well

Streaming Well is a healthcare focused, award-winning video production company which operates in the US and Europe....

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics